Evaluation of ALK, EGFR and PD-L1 Mutations in Pulmonary Carcinomas through Immunohistochemistry

Introduction: Lung cancer, with about 2.2 million new cases and 1.8 deaths, is the second most commonly diagnosed cancer leading cause of death in 2020. Immunohistochemistry (IHC) now used not only to diagnose classify lung tumors into subtypes, but also determine eligibility patients for different molecular-targeted therapies. 
 Objectives : Study ALK, EGFR PD-L1 mutations Pulmonary Carcinomas through immunohistochemistry examinations help prognosis that may benefit from target therapy. Detection possible links between EGFR, other variables such as age, sex, histological entity degree tumor differentiation. Materials Methodology: The study retrospective includes 266 who underwent biopsy at American Hospital period 2016-2020. Tissues obtained were subjected IHC examination using antibodies against factors PD-L1, etc. Results: showed out patients, 24% are females 76% males. average age was 61.8 years. No statistically significant relationship found gender differentiation adenocarcinomas. link ALK entity, a type pulmonary carcinomas. Conclusions one common cancers, mainly men, women. Nowadays, helps can respond therapy their prognosis. Therefore, use detect PDL-1 patient characteristics becoming increasingly necessary.